Dr. Feng Wang 王峰
Chief Physician, Research Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment and translational research for digestive tract tumors, including gastric, colorectal, esophageal, pancreatic, and biliary tract cancers.
Dr. Wang is a Researcher, Chief Physician, and Deputy Director of Internal Medicine at Sun Yat-sen University Cancer Center, and a Young Changjiang Scholar. Dr. Wang holds a PhD in Biomedical Sciences from the University of Texas MD Anderson Cancer Center and an MD from Sun Yat-sen University.
Professional roles
- Council Member, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Youth Council, China Anti-Cancer Association
- Vice Chair, Youth Committee, Professional Committee on Tumor Targeted Therapy, China Anti-Cancer Association
- Chair, Youth Committee, Guangdong Provincial Professional Committee on Tumor Targeted Therapy, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Feng). Papers usually list the name as Feng Wang or Wang F.
Selected publications
192 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Cell, 2026 (senior author): How far are we from multi-omics states to therapeutic targets in microsatellite-stable colorectal cancer?. PubMed 42913634
- Chin Med J (Engl), 2026 (senior author): Molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer: A comprehensive review. PubMed 42425097
- Nat Commun, 2026 (first author): Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study. PubMed 42901884
- Adv Sci (Weinh), 2026 (senior author): Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers. PubMed 42713665
- CA Cancer J Clin, 2026 (first author): Advances in therapeutic approaches to gastric cancer. PubMed 42751916
- J Comp Eff Res, 2026 (senior author): Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. PubMed 42583940
- Cancer Innov, 2026 (senior author): Annual Review of Systemic Medical Treatment for Colorectal Cancer in 2025. PubMed 41970467
- Gastroenterol Rep (Oxf), 2026 (senior author): Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study). PubMed 41767624
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion